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ABSTRACT
Objective: The objective of this selective EBM review is to determine: “Is platelet rich plasma
(PRP) injection an effective therapy in improving patient functional outcomes and decreasing
pain postoperatively in adults with meniscal repairs.”
Study Design: A systematic review of three randomized controlled trials (RCTs) published
between 2018 and 2019.
Data Sources: All three RCTs were discovered using PubMed, AMED, CINAHL Plus, and
Rehabilitation & Sports Medicine Source. The articles were published in English in peerreviewed journals and selected based on applicability to the clinical question.
Outcome Measured: Patients’ pain was assessed using the Visual Analog Scale (VAS) and the
Knee Injury and Osteoarthritis Outcome Score (KOOS) was used to measure patient quality of
life. Outcomes were assessed pre- and post-intervention, the mean change from baseline was
calculated once intervention was received.
Results: In the RCT by Kaminski et al. (2018), meniscal repair with PRP injection administered
at repair site provided significant improvement in quality of life postoperatively compared with
the control group with P < 0.01, but patient pain measured by the VAS assessment was found to
be non-significant between in the groups. In the RCT by Kaminski et al. (2019), there was no
difference in patient quality of life outcomes between trephination repair alone and trephination
with PRP, p-value was all non-significant, but the p-value was <0.05 and statistically significant
for pain between groups on the VAS score. Lastly, Elnemr et al. demonstrated improvement in
patient pain and quality of life with PRP injections administer at the meniscal repair site postoperatively compared to the control group with statistical significance of P < 0.05 for both
measures.
Conclusion: Two studies in this review demonstrated that PRP injection used in meniscal repairs
significantly improves patient pain and quality of life, and one study found that PRP injections
had no significant impact on these measures. Based on this review, the evidence for the
effectiveness of PRP injections in meniscal repairs is promising, but ultimately inconclusive and
further studies to explore this therapy are warranted.
Key Words: platelet rich plasma, tibial meniscus injuries, meniscal repair, surgery
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INTRODUCTION
The menisci are two c-shaped wedges of cartilaginous tissue located bilaterally between
the tibial plateau and femoral condyle that make up the knee joint. The menisci provide stability
to the knee by bearing the load of the knee while in flexion, they can tear acutely due to
traumatic injury or chronically from degenerative changes.1 Arthroscopy, a minimally invasive
“all inside” surgical approach, is used predominantly and partial or total meniscectomy, removal
of the injured meniscus, is the most common intervention performed¹. Recently, complete
surgical repair of the meniscus is favored instead, if possible, with or without biological or
medical adjuvants to promote healing and preserve functionality of the knee long-term.¹
In the United States, an estimated 850,000 arthroscopic meniscus surgeries will be
performed each year, making it a very common orthopedic surgery.1 Approximately 52–93% of
all meniscal repairs will heal and the overall failure rate is about 23.1%.2 In the United States the
cost of arthroscopic knee surgeries overall, which includes meniscus surgeries, estimates to $4
billion a year and the cost of surgery per individual patient can range anywhere from $5,000 $10,000.3 The incidence of meniscal tears is about 66 tears per 100,000 persons.1 The type and
location of tear impacts the functional status and pain levels of each individual patient, so not all
patients with a meniscus tear will seek healthcare.
The menisci are important supportive structure of the knee joint and it’s very common for
them to tear. In terms of repair, surgical repair with suturing is typically reserved for younger,
more active patients, while meniscectomy vs. repair is weighed in older or less active patients. 2
While PRP injections have been known and used in medicine since about the 1970s, there is little
evidence about the effect PRP injections can have for meniscus tear healing. 2 Typical treatment
of meniscal tears includes conservative treatment such as physical therapy and assistive devices
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and over the counter pain medication such as NSAIDs. Pain refractory to NSAIDs can be
managed with intraarticular corticosteroid or hyaluronic acid. Definitive treatment of a meniscal
tear is completed via surgical repair, which can include surgical techniques such as trephination
of the tear site and/or suturing with adjuvant therapies at the surgical site like fibrin glue or
growth factor administration, and in cases where repair is not possible or failed, a partial or total
meniscectomy may be performed.4 It is possible to inject PRP preparation at the site of meniscal
repair either during the time of repair or post-repair as an adjuvant to promote further healing of
the repair site. PRP injections involve taking a patient’s own blood to collect plasma with a
highly concentrated collection of platelets inject it into a variety of tissues. The platelets contain
growth factors, interleukins and cytokines that can promote the body’s natural healing process
and tissue regeneration at the injection site.5 In regard to meniscal repairs, the menisci are
relatively avascular, particularly in the inner two thirds, and the lack of blood flow poses risk of
surgical repair failure so the use of biological adjuvants like PRP injections at the site are being
investigated.5 Interleukins and cytokines help to initiate immune responses in the body and can
cause an inflammatory response when an injury occurs. They also play an important role in cell
proliferation, like creating new cells to help repair areas of damage, so the simple theory behind
PRP injections is to take concentrations of these inflammatory and essentially “rebuilding”
proteins and inject them into any area that is definitely in need of repair and rebuilding, but is
lacking in blood supply and these helpful proteins.
OBJECTIVE
The objective of this systematic review is to determine: “Is platelet rich plasma (PRP)
injection an effective therapy in improving patient functional outcomes and decreasing pain
postoperatively in adults with meniscal repairs.”
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METHODS
Studies were chosen based on validity, applicability to the clinical question, and
incorporation of patient-oriented outcomes. Further, they were selected if they fulfilled criteria
based on population, intervention, comparison, and outcome measured. All studies included in
this review were chosen independently by the writer and found by using key words “platelet rich
plasma”, “tibial meniscus injuries”, “meniscal repair”, and “surgery” in PubMed, AMED,
CINAHL Plus, Rehabilitation & Sports Medicine Source databases. All included studies were
required to be published between 2010 and 2020, published in peer reviewed journals, published
in English language, be randomized controlled trials, and all study participants had to be adults
aged 18+. Additionally, any studies that evaluated concomitant ligament or other knee injuries
with meniscal tears and any studies published prior to 2011 were excluded. Statistical analyses
used in the included studies included mean change from baseline in the VAS pain scale and
KOOS functional outcome assessments, and statistical significance using p-values and number
needed to treat (NNT).
The population criteria of the included studies examined adults ages 18-70 with meniscal
tears. Specific demographic information and characteristics are included in Table 1. The
intervention used in each study was PRP injection received at the site of repair. Kaminski et al.
(2018) used patients undergoing surgical meniscal repair with placebo injection as comparison,
Kaminski et al. (2019) used patients undergoing trephination repair without PRP injection as
comparison, and Elnemr et al. used patients who received surgical meniscus repair with no PRP
injections postoperatively as comparison. The outcomes measured that this selective EBM
focuses on are patient pain and quality of life.

Foschi, PRP meniscal repair 4
OUTCOMES MEASURED
All studies in this review utilized the VAS assessment to measure patient pain and the
KOOS assessment to measure quality of life. All patients were asked to complete both
assessments prior to undergoing surgical intervention to repair the meniscus. Patients then
completed the same two assessments post intervention, comparison and intervention groups were
assessed at the same times, though the studies did vary in how often and specifically when
patients were assessed post-intervention. Kaminski et al. (2018) specified that post-intervention
evaluation of pain and quality of life were taken at 42 months, while Elmner et al. had patient
complete post-intervention evaluations at 3 and 6 months. All studies had patients complete VAS
and KOOS assessments prior to intervention and after intervention, but there is some variability
in the length of time post intervention in which evaluation was completed.

Table 1. Demographics & Characteristics of Included Studies
Study
Type # Pts
Age
Inclusion Criteria
Exclusion
(yrs)
Criteria
Kaminski
2018
(1)

RCT

37

Adults
18-55
years
old

Patients aged 18–
55 years, with
complete vertical
longitudinal tear
>10 mm in length
on MRI, or
unstable peripheral
tear, meniscus
lesion in Cooper
zone 2; more than
4 mm from the rim,
and meniscus
injury 1–18 months
prior to surgery

Kaminski
2019
(2)

RCT

72

Adults
ages
18-70
years
old

Skeletally mature
patients aged 18–
70 years, chronic
horizontal tears on
MRI, tear located
in the

Arthritic
changes,
degeneration,
in the
meniscus,
meniscus
lesion in the
Cooper zone
0-1, injury >18
months prior
to surgery,
concomitant
surgical
procedures,
inflammatory
diseases
Arthritic
changes,
discoid
meniscus
axial leg
deformity,

W/D Interventions
2

Meniscus
surgical repair
with platelet
rich plasma
(PRP)
injection
received at the
repair site VS.
surgical repair
with placebo
injection at
repair site.

1

Percutaneous
trephination of
meniscal
tear(s) with
platelet rich
plasma (PRP)
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vascular/avascular
portion of the
meniscus, and
single tear of the
medial and/or
lateral meniscus
Elnemr
2019
(3)

RCT

30

Adults
ages
18-55

Patients aged 18 55 years, having
had complete
meniscal tear in
red-white zone,
surgical repair by
single surgeon, and
complain of pain
within 4 months
after repair.

concomitant
chondral
defects
Inflammatory
diseases,
chondral
defects
Patients with
diabetes,
autoimmune,
hematologic,
or cardiac
diseases,
infections,
other knee
injuries, and
anticoagulant/
NSAID use
within 5 days

injection
received at the
repair site VS.
trephination
without PRP

0

PRP injected
postoperatively
and intraarticularly at 1month
intervals for 6
injections total
VS. no PRP
injections
postoperatively

RESULTS
The first study discussed in Kaminski et al. (2018). The authors enrolled 37 adult patients
to undergo surgical meniscal repair. 2 were lost to follow-up, so ultimately 17 control group
members and 15 test group members were analyzed. All patients underwent surgical meniscal
repair by the same surgeon, the 17 control members were given a placebo injection at the time of
repair at the repair site and the 18 treatment group members were given a PRP injection at the
site of repair at the time of the repair. This study was double blinded so both patients and
clinicians were unaware of which type of injection was given. Post-operatively, patients
underwent the same rehabilitation guidelines and protocols. At 42 months, patients’ pain levels
and quality of life were assessed with the same VAS and KOOS assessments they completed
prior to operation. The VAS score for pain showed some improvement in the PRP-treated group
compared to the control group with a mean score of 0.84 compared to .89 respectively, but it
wasn’t found to be statistically significant. However, the KOOS score rating for Quality of Life
improved greatly in the PRP treated group compared to the control group with a mean score of
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80.90 and 66.18 respectively. The P-value was found to be statistically significant at .035, which
indicates that patients who received PRP injection at the meniscal repair site had significantly
improved quality of life compared to the control group post-operatively.
Table 2. Secondary Outcome Assessment at 42 months²
Control Group
PRP-Treated Group
VAS Score
KOOS Score –
Quality of Life

P-value

0.89 ± 0.08 (0.33–1.44)

0.84 ± 0.10 (0.04–1.65)

P = 0.15

66.18 ± 1.17 (57.94–74.42)

80.90 ± 1.09 (72.34–89.47)

P = 0.035

Data are presented as mean ± standard error (95% confidence interval)
Led by the same author, Kaminski et al. (2019) published a similar study a year later that
focused on the specific surgical meniscal repair technique known as trephination. 72 adults with
meniscus tears were included, 1 control member was lost to follow up, so in total 29 patients
were analyzed in the control group and 42 were analyzed in the treatment group. The control
group consisted of patients undergoing trephination surgical procedure for a meniscus repair with
placebo injection administered at the time of repair and the treatment group consisted of patients
undergoing trephination repair with PRP injection at the time of repair at the site of repair. This
study achieved partial blinding, the patients and raters were blinded, but clinicians were not. The
surgeries in both groups were performed by the same surgeon and postoperatively patients again
underwent the same rehabilitation and post-operative protocols. Patients’ pain levels and quality
of life were assessed with the same VAS and KOOS assessments they completed prior to
operation. The VAS score for pain showed improvement in the PRP group compared to the
control group with a mean score of 3.62 compared to 2.36 respectively and was found to be
statistically significant with p = 0.046. However, the KOOS score rating for Quality of Life was
found to not be statically significant between the control and treatment groups. Upon further
calculations, MCID scores provided in the study dichotomously allowed for the calculation of

Foschi, PRP meniscal repair 7
NNT, which was 17 for quality of life and 13 for pain. While it is not a precise measure, it
indicates that for every 17 people treated with trephination and PRP augmentation, one more will
have a clinically significant improvement. This study indicates that patients who received PRP
injection at the meniscal repair site with trephination had significantly improved pain, but not
significant quality of life improvement compared to the control group post-operatively.
Table 3. Patient-reported Outcome Measures4
Control Group
Control
Improved by
at least
MCID [%]
VAS Score
KOOS Score
– Quality of
Life

2.36 ± 0.0.09
(3.86–5.20)
32.67 ± 1.06
(22.93–42.41)

39
70

PRP Group

PRP Group
Improved
by at least
MCID [%]

P-value

3.62 ± 0.07 (2.82–
4.43)
28.43 ± 0.52
(22.23–34.64)

65

P = 0.046

76

P = 0.41

Data are presented as mean ± standard error (CI 95%) unless otherwise indicated.
The third study conducted by Elnemr et al. looked at the effects of PRP injections
injected at the site of meniscal repair post-operatively at 1-month intervals for a total of 6
injections over 6 months. The authors had participants complete the VAS assessment and KOOS
assessment pre-operatively and then at 3-months and 6-months post-operatively, for the purposes
of this review the 6-month post-operative scores are what will be considered. 30 participants
were recruited to this study, no patients were lost to follow-up, and 15 were randomized to the
control group and 15 were randomized to the treatment group. The authors of this study reported
it was double-blinded, though there is room for doubt here regarding complete blinding as the
participants were their own raters, no external raters were used to ensure full blindness of
patients. The same surgeon was used for all participants, but it was not disclosed by the authors
whether patients underwent the same rehabilitation protocol post-operatively. The control group
underwent meniscal tear surgical repair without any sort of injection post-operatively, and the
treatment group underwent surgical repair with 6 PRP injections post-operatively at 1-month
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intervals. As noted in the chart below, the control group showed scores of 38.4 for the VAS
assessment and 24.3 for the KOOS assessment, and the treatment group showed scores of 84.9
for VAS assessment and 42.2 for the KOOS assessment, which were both higher than the
treatment group indicating better resolution of pain and improved quality of life in life postoperatively with PRP injections. The p-values for both measures were less than .05 indicating
statistic significance in both measures within the treatment group.
Table 4. Comparison Between Both Groups Regarding Clinical Evaluation Parameters 5
PRP Group
Non-PRP Group
P-value
VAS Score
% Change

↓84.9 ± 6.9

↓38.4 ± 37.4

P = < 0.001

KOOS Score
% Change

↑42.2 ± 22.5

↑24.3 ± 18.8

P = 0.035

Statistically significant at P ≤ 0.05.
DISCUSSION
PRP injections are by no means a new technology, but the way the injections are utilized
in orthopedic treatment, particularly in meniscus repair is a relatively new pursuit of therapy.
Because of it’s relatively new use in the treatment specifically of surgical meniscus repair
augmentation, there is a limited number of recent studies to show the effects of this therapy.
Also, cost may be a barrier to patients in accessing PRP injection augmentation with meniscal
repair. Due to its relative newness and the lack of large scale studies demonstrating the efficacy
of PRP injections for meniscal repair augmentation, most insurances do not cover PRP injections
for this purpose so it is less likely for patients to pursue it as a treatment considering they would
have to pay out of pocket for it.
The studies included in this review have demonstrated that there is some efficacy to the
use of PRP injection augmentation of meniscal surgical repairs. Kaminski et al. (2018) showed
statistically significant improvement in patient pain post-operatively with the use of PRP
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injection during surgical repair, and Kaminski et al. (2019) showed statistically significant
improvement in quality of life post-operatively. Elmner et al. showed statistical significance in
improvement of both pain and quality of life post-op with PRP use. The results of this review
show that there is some good efficacy for the use of PRP augmentation in meniscus repair,
though some of the evidence was conflicting.
All three studies carry limitations of their own that impact the interpretation of the
information they provide. In a positive aspect, all the studies included both male and female
participants, making the results of the studies generalizable to the population in terms of gender.
All studies were comprised of a relatively small sample size, larger study samples are warranted
to make the results more generalizable to the population.
Both studies by Kaminski et al. disclosed that patients were given the same rehabilitation
protocols post-operatively. This strengthens the validity of the results as we can be assured the
post-operative rehabilitation of patients was not different and did not put any patients at
advantage or disadvantage over others in terms of rehab and healing that could have impacted
the levels of pain and quality of life patients experienced. Elnemr et al. did not disclose if
patients were given a specific standardized rehabilitation protocol, leaving room for the
possibility that patients could have had varying levels or experiences of post-op rehab that could
have impacted their experiences of pain and quality of life post-operatively.
All three studies reported that they used the same method of preparation for their PRP
injections used in surgery. It is worth noting though that the preparation methods were not
identical between all the studies. Given how new the technology of PRP injections for meniscal
repairs is, there is not yet a standardized protocol for PRP preparation, so it is possible that the
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PRP preparations that were injected in participants were not the same between the 3 studies,
which decreases validity and could pose a challenge with replicating future studies.

CONCLUSIONS
Overall this review found that there was some conflicting evidence about the results of
PRP injections used in meniscal surgical repairs for the improvement in patient pain and quality
of life post-operatively, so it is not possibly to determine if PRP injections for meniscal repairs
are completely effective based on this review alone. Only one trial showed significant
improvement in patient pain and quality of life post-operatively, while one showed only
improvement in pain and one showed only improvement in quality of life. While this is
encouraging, larger sample sizes and additional trials could benefit determining the complete
efficacy of PRP injection use in meniscal repairs.
Another possibility to be explored in further studies would be to look exclusively at using
PRP injections in meniscal tears that do not undergo surgical repair. For patients that are either
not surgical candidates due to underlying comorbidities, or patients that do not want to pursue
surgical repair immediately, PRP injections at the site of a tear may offer some relief in
symptoms and promote some healing based on their mechanisms of healing. Additionally, if
patients do decide to pursue surgical repair, it would be interesting to see if the administration of
PRP injection to the site of a tear impacts the resulting patient outcomes after a surgical repair of
the site.
PRP injections have proven to be beneficial in other areas of orthopedic soft tissue
injuries, and they are considered to be safe to use in patients since the PRP preparation is made
from the patient’s own blood which is a reassuring fact when considering the use of PRP
injection in experimental settings. The data available on PRP injection use in meniscal repair is
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so far reassuring, and it will be exciting to see as more data comes out in larger studies to
determine to overall efficacy of this treatment.
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